Achieve Life Sciences

OverviewSuggest Edit

Achieve Life Sciences is a biopharmaceutical company that develops and commercializes therapies that address treatment resistance in cancer patients. It is developing Apatorsen to block the production of heat shock protein 27, a cell-survival protein expressed in various types of cancers, including bladder, prostate, breast, pancreatic, and non-small cell lung cancer. The Company is also working on cytisine-based therapies as a widely available treatment option for nicotine addiction.

TypePublic
Founded1995
HQSeattle, US
Websiteachievelifesciences.com

Latest Updates

Employees (est.) (Dec 2019)14(+8%)
Revenue (FY, 2019)$0
Share Price (May 2020)$0.4

Key People/Management at Achieve Life Sciences

Richard Stewart

Richard Stewart

Chairman and Chief Executive Officer
Anthony Clarke

Anthony Clarke

Director & Chief Scientific Officer
John Bencich

John Bencich

Vice President and Chief Financial Officer
Scott Cormack

Scott Cormack

Director
Cindy Jacobs

Cindy Jacobs

Executive VP and Chief Medical Officer
Kirsten Anderson

Kirsten Anderson

Vice President, Clinical Operations
Show more

Achieve Life Sciences Office Locations

Achieve Life Sciences has offices in Seattle, Bothell and Vancouver
Seattle, US (HQ)
520 Pike St #2250
Bothell, US
19820 North Creek Pkwy #201
Vancouver, CA
1040 W Georgia St #1030
Show all (3)

Achieve Life Sciences Financials and Metrics

Achieve Life Sciences Revenue

USD

Net income (Q1, 2020)

(3.3m)

Market capitalization (29-May-2020)

15.3m

Closing stock price (29-May-2020)

0.4

Cash (31-Mar-2020)

12.2m

EV

3.5m
Achieve Life Sciences's current market capitalization is $15.3 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

General and administrative expense

6.2m7.8m9.9m10.6m11.8m8.9m3.5m6.9m6.9m

R&D expense

21.6m39.9m55.3m46.2m25.1m14.8m3.1m5.9m9.7m

Operating expense total

27.8m49.4m65.2m56.8m36.9m23.7m6.6m12.8m16.5m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

General and administrative expense

1.5m1.5m1.7m2.0m2.0m2.5m2.5m2.5m2.8m2.7m2.5m2.7m3.1m3.1m2.3m2.5m1.9m2.5m2.3m1.6m1.8m1.8m1.8m1.9m1.6m1.9m1.8m

R&D expense

5.4m3.8m5.1m6.3m12.9m10.9m13.3m18.0m16.9m9.9m9.6m3.7m6.5m8.3m4.6m4.7m3.8m912.0k777.0k825.0k1.2m1.0m1.5m4.1m2.0m1.8m1.5m

Operating expense total

6.9m5.3m6.8m8.4m14.9m13.4m15.7m20.5m19.7m12.6m12.0m6.4m9.6m11.4m7.4m7.1m5.6m3.4m3.1m2.4m3.0m2.8m3.3m5.9m3.7m3.7m3.4m

EBIT

(5.0m)(4.1m)(5.5m)5.9m8.3m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

28.5m18.1m14.6m27.9m34.3m15.2m5.3m9.5m16.7m

Accounts Receivable

812.0k714.0k8.7m5.7m14.0k32.0k9.0k7.0k8.0k

Prepaid Expenses

1.2m3.8m5.8m2.2m2.0m393.0k926.0k662.0k

Inventories

USDY, 2020

EV/CFO

-0.8 x

Financial Leverage

1.1 x
Show all financial metrics

Achieve Life Sciences Online and Social Media Presence

Embed Graph

Achieve Life Sciences News and Updates

Achieve Life Sciences, University of Bristol, and Oracle Corporation Announce Study Results Demonstrating Potential for Accelerated Speed of Drug Discovery

SEATTLE and VANCOUVER, British Columbia, Jan. 13, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), University of Bristol, and Oracle Corporation (NYSE: ORCL) today announced the outcome of a study using Oracle's high-performance cloud infrastructure to potentially improve...

Achieve Life Sciences Announces Completion of Meeting with the U.S. Food & Drug Administration (FDA) on Cytisinicline Smoking Cessation Phase 3 Clinical Development Program

SEATTLE and VANCOUVER, British Columbia, Dec. 9, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today...

Achieve Life Sciences to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 6, 2019

SEATTLE and VANCOUVER, British Columbia, Oct. 31, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today...

Achieve Life Sciences Announces Presentation of Cytisinicline Data at Society for Research on Nicotine & Tobacco Oceania (SRNT-O) Inaugural Conference

SEATTLE, Wash. and VANCOUVER, British Columbia, Oct. 24, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today...

Achieve Life Sciences Announces Completion of Maximum Tolerated Dose Study

SEATTLE and VANCOUVER, British Columbia, Sept. 30, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced completion of their...

Achieve Life Sciences Announces Final Phase 2b ORCA-1 Trial Data Presented at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference

SEATTLE and VANCOUVER, British Columbia, Sept. 13, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that two...
Show more

Achieve Life Sciences Blogs

Achieve Life Sciences, Inc. Announces Closing of $13.8 Million Underwritten Public Offering, Including Full Exercise of Overallotment Option

SEATTLE, Wash. And VANCOUVER, British Columbia, December 19, 2019 – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the closing…

Achieve Life Sciences Announces Completion of Meeting with the U.S. Food & Drug Administration (FDA) on Cytisinicline Smoking Cessation Phase 3 Clinical Development Program

SEATTLE, Wash. and VANCOUVER, British Columbia, December 9, 2019 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced an update o…

Achieve Life Sciences to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 6, 2019

SEATTLE, Wash. and VANCOUVER, British Columbia, October 31, 2019 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it wil…

Achieve Life Sciences Announces Presentation of Cytisinicline Data at Society for Research on Nicotine & Tobacco Oceania (SRNT-O) Inaugural Conference

SEATTLE, Wash. and VANCOUVER, British Columbia, October 24, 2019 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that data f…

Achieve Life Sciences Announces Final Phase 2b ORCA-1 Trial Data Presented at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference

SEATTLE, Wash. and VANCOUVER, British Columbia, September 13, 2019 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that two presentations featuring…

Achieve Life Sciences to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 8, 2019

SEATTLE, Wash. and VANCOUVER, British Columbia, July 30, 2019 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that it will report its second quarte…
Show more

Achieve Life Sciences Frequently Asked Questions

  • When was Achieve Life Sciences founded?

    Achieve Life Sciences was founded in 1995.

  • Who are Achieve Life Sciences key executives?

    Achieve Life Sciences's key executives are Richard Stewart, Anthony Clarke and John Bencich.

  • How many employees does Achieve Life Sciences have?

    Achieve Life Sciences has 14 employees.

  • Who are Achieve Life Sciences competitors?

    Competitors of Achieve Life Sciences include Sareum Holdings, Akrevia Therapeutics and tella.

  • Where is Achieve Life Sciences headquarters?

    Achieve Life Sciences headquarters is located at 520 Pike St #2250, Seattle.

  • Where are Achieve Life Sciences offices?

    Achieve Life Sciences has offices in Seattle, Bothell and Vancouver.

  • How many offices does Achieve Life Sciences have?

    Achieve Life Sciences has 3 offices.